Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have completed the rolling submission to the U.S. Food and...
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US Patent and Trademark Office (USPTO) has granted a new drug substance...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that an article about long-term health outcomes of the investigational ...
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company's First Quarter Report for January - March 2022 on Thursday, April 28, 2022,...
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has announced that the company's partner AbbVie has decided to terminate its collaboration with...
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company and its collaboration partner Eisai will both present data relating...
BioArctic AB:s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has initiated a submission to the Pharmaceuticals and Medical Devices Agency (PMDA) of ...
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) continues to build the Nordic commercial organization ahead of a potential launch of the company's...
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company's Full Year Report for January – December 2021 on Thursday, February 3, 2022, ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that lecanemab, an investigational anti-amyloid beta (Aβ) protofibril...
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today gave an update on the company's development project ND3014. For the first time, it was announced ...
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) and partner Eisai held several oral presentations at the 14th Clinical Trials on Alzheimer's Disease...
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has published an article in Neurobiology of Disease describing new preclinical data for the...
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) and partner Eisai today announced that they will hold several oral presentations revealing new data on ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) Annual General Meeting on May 6, 2021, adopted an instruction regarding the appointment of the...
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company's Interim Report for the period January – September 2021 on Thursday, October ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that they have initiated a rolling submission to the U.S. Food and...
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will present new preclinical data for the investigational anti-α-synuclein antibody ABBV-0805 at the...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai held several presentations at the Alzheimer's Association International Conference...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will hold several presentations at the Alzheimer's Association International...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the U.S. Food and Drug Administration (FDA) has granted...
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the Japanese Patent Office (JPO) has allowed the company's Japanese patent...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced the publication of an article, A Randomized, Double-Blind Phase 2b...
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company's Interim Report for the period January - March 2021 on Wednesday, April 21,...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.